Skip to main content

Table 2 IgG glycome composition in gastric cancer patients with or without response to NACT

From: Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling

IgG glycome

Traits (composition)

Mean NRGa)

Mean (RGa)

P value

AUC

Confidence interval (95%)

Directly detected glycans

GP1 (H3N3F1)

0.137

0.182

0.048

0.678

0.524–0.832

GP2 (H3N4)

0.623

0.828

0.075

0.658

0.501–0.816

GP3 (H3N5)

0.013

0.005

0.179

0.568

0.406–0.730

GP4 (H3N4F1)

22.580

27.448

0.003

0.771

0.628–0.913

GP5 (H5N2)

0.157

0.144

0.460

0.474

0.309–0.639

GP6 (H3N5F1)

6.588

7.577

0.042

0.654

0.498–0.811

GP7 (H4N4)

0.353

0.348

0.902

0.519

0.352–0.687

GP8 (H4N4F1(6))

20.344

19.628

0.264

0.622

0.462–0.783

GP9 (H4N4F1(3))

10.108

9.925

0.678

0.541

0.372–0.709

GP10 (H4N5F1(6))

6.424

6.097

0.446

0.462

0.296–0.629

GP11 (H4N5F1(3))

0.691

0.725

0.542

0.451

0.286–0.616

GP12 (H5N4)

1.005

0.820

0.276

0.539

0.374–0.705

GP13 (H5N5)

0.033

0.014

0.209

0.568

0.406–0.731

GP14 (H5N4F1)

15.783

12.944

0.007

0.790

0.650–0.930

GP15 (H5N5F1)

1.840

1.496

0.017

0.712

0.559–0.865

GP16 (H4N4F1S1(3))

2.313

2.255

0.657

0.568

0.404–0.733

GP17 (H5N4S1)

0.620

0.521

0.146

0.577

0.413–0.741

GP18 (H5N4F1S1)

7.218

5.976

0.028

0.710

0.559–0.861

GP19 (H5N5F1S1)

0.778

0.737

0.446

0.589

0.424–0.755

GP20 (H5N4F2S1)

0.027

0.011

0.168

0.571

0.409–0.733

GP21 (H5N4S2)

0.495

0.519

0.692

0.528

0.361–0.696

GP22 (H5N5S2)

0.003

0.002

0.622

0.555

0.392–0.718

GP23 (H5N4F1S2)

0.835

0.792

0.689

0.582

0.414–0.750

GP24 (H5N5F1S2)

1.033

1.006

0.859

0.484

0.317–0.651

Main summarized traits

GPN

86.682

88.182

0.059

0.642

0.482–0.802

S1 total

10.929

9.489

0.029

0.695

0.543–0.847

S2 total

2.364

2.318

0.871

0.528

0.360–0.695

S total

13.292

11.808

0.061

0.642

0.482–0.802

G0 total

29.941

36.040

0.002

0.773

0.630–0.917

G1 total

37.920

36.724

0.064

0.685

0.531–0.839

G2 total

18.663

15.273

0.006

0.798

0.658–0.939

F total

94.572

94.798

0.505

0.487

0.319–0.654

F neutral

97.473

97.556

0.797

0.534

0.365–0.703

F sialo

91.669

90.941

0.185

0.623

0.463–0.783

B total

17.402

17.660

0.770

0.531

0.365–0.697

B neutral

17.998

18.007

0.993

0.510

0.343–0.677

B sialo

13.650

14.661

0.413

0.565

0.400–0.730

Gal-ratio

0.370

0.526

< 0.001

0.776

0.633–0.919

FG0

0.238

0.290

0.002

0.768

0.625–0.911

FG1

0.322

0.311

0.121

0.633

0.477–0.790

FG2

0.168

0.136

0.006

0.786

0.647–0.925

  1. aRG, patients with response to NACT; NRG, patients without response to NACT; H, Mannose; N, N-acetylglucosamine; F, Fucose; S, N-acetylneuraminic acid; italic font indicates the trait exist significant difference
Back to article page

Clinical Proteomics

ISSN: 1559-0275